These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 10355003)

  • 1. [MS Therapy Consensus Group. Immunomodulating staged therapy of multiple sclerosis].
    Nervenarzt; 1999 Apr; 70(4):371-86. PubMed ID: 10355003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon beta and multiple sclerosis: look at the evidence.
    Patti F; Reggio A
    Int J Clin Pract Suppl; 2002 Sep; (131):23-32. PubMed ID: 12564809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T; Bereczki D
    Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early treatment of multiple sclerosis with Rebif (recombinant human interferon beta): design of the study.
    Comi G; Barkhof F; Durelli L; Edan G; Fernandez O; Filippi M; Hartung HP; Hommes OR; Seeldrayers P; Soelberg-Sorensen P
    Mult Scler; 1995; 1 Suppl 1():S24-7. PubMed ID: 9345394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon beta-1b in secondary progressive multiple sclerosis--outline of the clinical trial.
    Polman CH; Dahlke F; Thompson AJ; Ghazi M; Kappos L; Miltenburger C; Pozilli C
    Mult Scler; 1995; 1 Suppl 1():S51-4. PubMed ID: 9345400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-beta1b in multiple sclerosis.
    Buttmann M; Rieckmann P
    Expert Rev Neurother; 2007 Mar; 7(3):227-39. PubMed ID: 17341170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapy of multiple sclerosis with interferon-beta-1b. Educating the patient and managing side-effects].
    Walther EU; Dietrich E; Hohlfeld R
    Nervenarzt; 1996 Jun; 67(6):452-6. PubMed ID: 8767199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Interferon therapy of multiple sclerosis].
    Jensen D
    Tidsskr Nor Laegeforen; 1999 Sep; 119(21):3142-5. PubMed ID: 10522481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon beta-1a: analysis of the PRISMS study.
    Freedman MS; Forrestal FG
    Mult Scler; 2008 Nov; 14(9):1234-41. PubMed ID: 18632774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [10 years of interferon treatment in multiple sclerosis. Does the future belong to high-dose therapy?].
    MMW Fortschr Med; 2003 May; 145 Suppl 2():108. PubMed ID: 14579501
    [No Abstract]   [Full Text] [Related]  

  • 12. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P
    Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.
    Schwid SR; Thorpe J; Sharief M; Sandberg-Wollheim M; Rammohan K; Wendt J; Panitch H; Goodin D; Li D; Chang P; Francis G; ;
    Arch Neurol; 2005 May; 62(5):785-92. PubMed ID: 15883267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnosis and treatment of multiple sclerosis. Update, 2003].
    Jarius S; Hohlfeld R; Voltz R
    MMW Fortschr Med; 2003 May; 145 Suppl 2():88-91, 93, 95. PubMed ID: 14579493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon beta-1A: new preparation. A short-term impact on the course of multiple sclerosis.
    Prescrire Int; 1998 Oct; 7(37):142-3. PubMed ID: 10915418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Escalating immunotherapy of multiple sclerosis.Austrian-German- Swiss Multiple Sclerosis Therapy Consensus Group [MSTCG].
    Rieckmann P; Toyka KV
    Eur Neurol; 1999; 42(3):121-7. PubMed ID: 10529535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A short history of beta-interferon therapy of multiple sclerosis].
    Stock G; Horowski R
    Med Klin (Munich); 2001 Sep; 96 Suppl 1():3-9. PubMed ID: 11603113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of multiple sclerosis--current practice and future directions.
    Tullman MJ; Lublin FD; Miller AE
    J Rehabil Res Dev; 2002; 39(2):273-85. PubMed ID: 12051470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early treatment.
    Comi G
    Neurol Sci; 2006 Mar; 27 Suppl 1():S8-12. PubMed ID: 16708191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials.
    Río J; Nos C; Tintoré M; Borrás C; Galán I; Comabella M; Montalban X
    Ann Neurol; 2002 Oct; 52(4):400-6. PubMed ID: 12325067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.